Merck, a leading science and technology company has appointed Ramsey Morad as Regional Vice President for the Healthcare business in Middle East, Africa, Turkey and Russia & CIS (MEAR).
According to a release distributed by African Media Agency (AMA), the appointment which took place recently will now make Morad now responsible for leading all business operations of Merck’s Healthcare business in this region.
Ramsey Morad, Regional Vice President for the Healthcare business in Middle East, Africa, Turkey and Russia & CIS (MEAR)
Morad is a well-regarded and experienced pharmaceutical executive with more than 25 years of industry experience across Europe, the Middle East and Africa.
“I am very excited to join Merck, a leader in science and technology, and head such a dedicated and driven organization. With its innovative, research-driven, specialty healthcare solutions, Merck is well-positioned to respond to the patients’ needs across the region and help them live a better life. I look forward to contributing to that by expanding our portfolio as well as extending its reach,” said Morad.
Merck’s Healthcare business in MEAR is represented in the therapeutic areas of General Medicine and Endocrinology (including Cardiometabolic Care), Fertility, Neurodegenerative Diseases and Oncology.
Joining from Allergan, Morad was the VP and Region Head of India, Middle East and Africa, leading the organization across 24 markets. Prior to Allergan, Morad was with Shire, in charge of the Eurasia, Middle East and Africa Region, where he led the integration efforts with Baxalta, established and expanded the company’s geographical footprint. Prior to Shire, Morad spent 17 years with MSD working in different roles of increasing responsibility across 6 countries including in regional leadership, general management and regional marketing.
Morad is a pharmacist with an MBA from Henley Business School. He was born and raised in the United States and over the years had the opportunity to live and work in several countries in Europe and the Middle East.
Morad is a well-regarded and experienced pharmaceutical executive with more than 25 years of industry experience across Europe, the Middle East and Africa.
“I am very excited to join Merck, a leader in science and technology, and head such a dedicated and driven organization. With its innovative, research-driven, specialty healthcare solutions, Merck is well-positioned to respond to the patients’ needs across the region and help them live a better life. I look forward to contributing to that by expanding our portfolio as well as extending its reach,” said Morad.
Merck’s Healthcare business in MEAR is represented in the therapeutic areas of General Medicine and Endocrinology (including Cardiometabolic Care), Fertility, Neurodegenerative Diseases and Oncology.
Joining from Allergan, Morad was the VP and Region Head of India, Middle East and Africa, leading the organization across 24 markets. Prior to Allergan, Morad was with Shire, in charge of the Eurasia, Middle East and Africa Region, where he led the integration efforts with Baxalta, established and expanded the company’s geographical footprint. Prior to Shire, Morad spent 17 years with MSD working in different roles of increasing responsibility across 6 countries including in regional leadership, general management and regional marketing.
Morad is a pharmacist with an MBA from Henley Business School. He was born and raised in the United States and over the years had the opportunity to live and work in several countries in Europe and the Middle East.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries. Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.
